Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Critical Care
When would you be comfortable with using HHFNC rather than NIV in patients with acute respiratory failure?
Do the findings of the
RENOVATE
trial influence your approach?
Related Questions
What are your thoughts on trending beta-hydroxybutyrate once a diagnosis of DKA is already established?
How do you use cardiac POCUS to potentially defer formal echocardiogram in patients presenting with an acute pulmonary embolism?
Do you use MRSA nares PCR to influence antibiotic selection for non-respiratory infections?
What tidal volume or minute ventilation goals do you target when titrating NIPPV in a patient with a hypercapneic COPD exacerbation?
When do you recommend limited or targeted respiratory pathogen testing versus a full respiratory pathogen panel in a patient presenting with URI symptoms?
What is the role of mechanical circulatory support in mixed cardiogenic vasodilatory shock?
What are the best techniques to reduce POCUS artifact and increase the diagnostic accuracy of lung ultrasound?
How do you weigh the risk of urinary catheter or fecal management system placement with that of soiling sacral wounds?
How do you approach caring for patients admitted with decompensated CHF, but who also exhibit hypotension and do not have overt signs of hypervolemia on exam?
Is there any evidence to support further uptitration of dobutamine beyond 5mcg/kg/min for patients with advanced HF and/or cardiogenic shock, or should further investigation into potential MCS be considered at that point?